Industry News
Pharmaceutical Industry News
With positive results from a phase…
With positive results from a phase 3 trial of Ebglyss, Eli Lilly is set up to make the IL-13 inhibitor available to a younger group of patients with atopic dermatitis.
Johnson & Johnson is suing a…
Johnson & Johnson is suing a former oncology medical affairs employee who is now “employed by” Summit Therapeutics, alleging a massive and “malicious” stealing of trade secrets.
Kerendia, also known as…
Kerendia, also known as finerenone, met the mark in Bayer’s late-stage Find-CKD study in adult patients with chronic kidney disease (CKD) who don’t have diabetes, allowing the study to hit its primary endpoint. The drug
Cuando los medicamentos para perder peso no funcionan
Fármacos como Wegovy y Zepbound han sido aclamados como tratamientos milagrosos. Pero una de cada 10 personas es lo que los científicos llaman “no respondedores”.
The CEO’s 2025 pay was a sizeable…
The CEO's 2025 pay was a sizeable bump over the $24.6 million he collected in 2024, making for his second largest pay package since taking the helm in 2019.
GSK has secured an FDA expansion…
GSK has secured an FDA expansion for its respiratory syncytial virus vaccine, Arexvy, for adults ages 18 to 49 who are at increased risk of lower respiratory tract disease caused by the virus. The green
From its 17-year development cycle…
From its 17-year development cycle through to its commercial launch, production has always been in Yeztugo’s DNA. And, for the twice-yearly pre-exposure prophylaxis medication—which Gilead Sciences has positioned as a key tool in the fight
Simtra BioPharma Solutions was…
Simtra BioPharma Solutions was issued a warning letter by the FDA after an inspection uncovered a number of problems at the CDMO’s production plant in Halle, Germany.
The FDA has rejected Hyloris…
The FDA has rejected Hyloris Pharmaceuticals' antiviral valacyclovir, an oral suspension for infections caused by herpes simplex and varicella-zoster viruses becasue of manufacturing problems.
When Weight-Loss Drugs Don’t Work
Drugs like Wegovy and Zepbound have been hailed as miracle treatments. But one in 10 people are what scientists call “non-responders.”
Eli Lilly is making investments in…
Eli Lilly is making investments in China, Japan and South Korea. Pfizer has broken into obesity thanks to a Chinese nod won by its local partner Sciwind Biosciences. Astellas' CEO attributed a better-than-expected reimbursement price
While much of the company’s…
While much of the company’s recent focus has remained on beefing up its U.S. infrastructure, Eli Lilly has for the second time this week made moves to raise capacity for its medicines overseas, and once
During a quarterly conference…
During a quarterly conference call, executives from Legend Biotech showed little concern for a potential threat to its lone commercial product, multiple myeloma CAR-T Carvykti. Oddly enough, the threat is coming from its Carvykti parter,
The new platform combines seven…
The new platform combines seven different adverse event dashboards into one, an effort that could save the agency $120 million over five years, it said.
According to a new team-up between…
According to a new team-up between Eisai and Pokémon, when it comes to healthy sleep habits, people of all ages have gotta catch ’em all.
Eli Lilly—which has already…
Eli Lilly—which has already staged multiple efforts in court to protect sales of its diabetes and obesity meds Mounjaro and Zepbound from compounders—is launching a new salvo focused on the potential safety risks behind a
The rare disease field is…
The rare disease field is navigating a period of significant turbulence, what with a “temperamental” FDA and competition for investor attention from mainstream blockbusters like obesity treatments. Yet, despite the “stormy waters,” global sales of
As AstraZeneca kicks off the third…
As AstraZeneca kicks off the third year of its hockey-themed “Get Body Checked Against Cancer” campaign, the pharma has tapped two celebs known for their work both on and off the ice.
Eli Lilly continued staggering…
Eli Lilly continued staggering sales growth in the fourth quarter, nearly tripling that of any other top 25 drugmaker. Meanwhile, most companies are expecting a slowdown in growth in 2026.
Veeva Systems, which offers life…
Veeva Systems, which offers life sciences companies cloud-based commercial management software and business consulting services, is venturing into the consumer-facing side of things with the acquisition of Ostro.